How this Nasdaq-U.K.-listed Chinese biotech is revolutionizing cancer treatment

Chi-Med has been granted three U.S. Food and Drug Administration Fast Track Designations for its cancer drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.